Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?

Annals of the Rheumatic Diseases

Volumn 69, Issue 2, 2010, Pages 387-393

  Finckh, A ^a   Ciurea, A ^b   Brulhart, L ^a   Moller B ^c   Walker, U A ^d   Courvoisier, D ^a   Kyburz, D ^b   Dudler, J ^e   Gabay, C ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SWITZERLAND; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 75749106664     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.105064     Document Type: Article

References (32)

1. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
2. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
3. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
4. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
5. Redlich K, Schett G, Steiner G, et al. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade. Arthritis Rheum 2003;48:3308-19.
6. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis 2006;65:746-52.
7. Lutt JR, Deodhar A. Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists. Drugs 2008;68:591-606.
8. Haraoui B. Is there a rationale for switching from one anti-tumor necrosis factor agent to another? J Rheumatol2004;31:1021-2.
9. Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007;66:893-9.
10. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46:1191-9.
11. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20.
12. Gullick N, Da Silva C, Kirkham B. Failure of adalimumab in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2007;56(Suppl):S183.
13. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo controlled trial. Ann Rheum Dis 2008;67:1516-23.
14. Cohen S, Emery P, Greenwald M, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
15. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23.
16. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
17. Venkatachalam S, Roskell S, Suchitra R, et al. Rituximab may be more effective than switching to an alternative TNF inhibitor in rheumatoid arthritis patients who have failed other TNF inhibitors [abstract]. Rheumatology (Oxford) 2008;47(suppl):ii28.
18. Blom M, Kievit W, den Broeder A, et al. Comparison of the effectiveness of rituximab and a third TNF blocking agent after failure of two TNF blocking agents in daily clinical practice [abstract]. Arthritis Rheum 2008;58:S304.
19. van Vollenhoven R, Carli CC. The efficacy of rituximab in patients with rheumatoid arthritis (RA) who previously failed one or two anti-TNFs as compared to the efficacy of switching between anti-TNFs: a registry study [abstract]. Arthritis Rheum 2008;58:S899.
20. Uitz E, Fransen J, Langenegger T, et al. Clinical quality management in rheumatoid arthritis: putting theory into practice. Swiss Clinical Quality Management in rheumatoid arthritis. Rheumatology (Oxford) 2000;39:542-9.
21. Finckh A, Simard JF, Duryea J, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006;54:54-9.
22. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
23. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81.
24. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
25. Smolen J, Kay J, Doyle M, et al. Golimumab, a new human anti-TNF-alpha monoclonal antibody, subcutaneously administered every 4 weeks in patients with active rheumatoid arthritis who were previously treated with anti-TNF-alpha agent(s): results of the randomized double-blind, placebo-controlled trial [abstract]. Ann Rheum Dis 2008;67(suppl II):50-1.
26. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8:R29.
27. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 2004;63:607-8; author reply 608.
28. Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008;47: 507-13.
29. Buch MH, Bingham SJ, Seto Y, et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. Arthritis Rheum 2004;50:725-8.
30. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
31. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771-4.
32. Solau-Gervais E, Laxenaire N, Cortet B, et al. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford) 2006;45:1121-4.